Drug Trial Radar · NCT01847924
NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects
Last checked: Nov 19, 2026Latest source record: Jul 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
103
Actual
Start
Mar 2013
Primary completion
Apr 2018
Study completion Apr 2018
Sponsor
- Lead sponsor
- National University Hospital, SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients who have suffered from stroke may develop problems with thinking. Moreover, such patients have a high risk of becoming demented, more dependent or dying. Therefore, further studies are urgently needed to find effective and safe treatments. Neuroaid is a Traditional Chinese Medicine which has been shown to stimulate growth of brain cells and connections in animals. Neuroaid may improve blood flow in the brain and functional recovery after stroke in patients. Neuroaid-II is a simplified formula with only the main 9 herbal ingredients of the original formula and no animal ingredients. The NEURoaid II (MLC 901) assessment in cognitively Impaired not demented subjects: a pilot double blind, placebo-controlled randomized Trial on Efficacy and Safety (NEURITES) Study is a 24-week, early phase trial of Neuroaid-II in patients who have thinking problems after stroke. The study aims to investigate the effectiveness of the study drug in improving cognitive performance. The safety of the study drug will be closely monitored using adverse events, laboratory tests and vital signs. The trial is important as it aims to set new standards for the scientific evaluation of Asian Traditional Medicine for integration into standard medicine practice. It may potentially establish a novel therapeutic approach for improving cognition after stroke.
Conditions
- Cognitive Impairment
Interventions
MLC901Drug
24 weeks intervention with orally MLC901. 2 capsules 3 times a day
PlaceboDrug
24 weeks intervention with orally placebo. 2 capsules 3 times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparative change on executive functionTime frame: Baseline to 24th week(24 week)
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
University of Santo Tomas Hospital
Manila, National Capital Region, Philippines
National University Hospital
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
National Neuroscience Institute
Singapore, Singapore
National Geriatric Hospital
Hanoi, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.